USO 24065
A Phase 2 study of BPM31510 with Vitamin K1 in subjects with newly diagnosed glioblastoma (GB) (BPM31510IV-11)
Disease Types: Neurology
Eligibility Requirements:
Newly diagnosed, pathologically verified glioblastoma
(WHO 2016 or C-IMPACT, update 6) with any
evidence of residual disease
• No prior RT, chemo, IO, or targeted agents for the
lesion being treated
• KPS ≥60
• Day 1 must be min of 15 days and max of 50 days
from definitive neurosurgery
For more information on this trial CLICK HERE .
Available at: